Navigating Asthma Control: A Severe Asthma Roadmap for Improved Diagnosis and Personalized Treatment
August 7, 2019
August 7, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided in collaboration with Mount Sinai - National Jewish Health Respiratory Institute and National Jewish Health.
Supported by an educational grant from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline and Novartis Pharmaceuticals Corporation .
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
- ABIM Diplomates — maximum of 0.5 ABIM MOC medical knowledge points.
All other healthcare professionals completing this course will be issued a statement of participation.
This activity has been designed to meet the educational needs of allergists, pulmonologists, primary care physicians, pediatricians and physician assistants who treat patients with asthma.
This case-based enduring activity will cover the diagnosis, treatment and management of patients with severe asthma.
Upon completion of this activity, participants should be able to:
- Apply current management guidelines to diagnose asthma correctly, optimize inhaled therapy, address comorbidities, and recognize when asthma is not well controlled.
- Review evidence related to potential long-term effects of oral corticosteroids and assess their role in asthma management in the era of biologic therapies.
- Identify key features of moderate to severe asthma that are targets for biologic therapies.
- Individualize biologic and non-biologic therapies for patients based on their inflammatory phenotype, coexisting conditions, and other individual factors.
Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director of The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health, Denver, CO
Linda Rogers, MD
Associate Professor of Medicine
Pulmonary, Critical Care and Sleep Medicine
Director, Clinical Asthma Program
Icahn School of Medicine at Mount Sinai
Mount Sinai -- National Jewish Health Respiratory Institute, NYC
Physicians Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
National Jewish Health designates this live educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all program faculty, content developers, CME approval committee, and those in position to control the content of this activity disclose any significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
All CME educational activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.
Michael E. Wechsler, MD, MMSc
- Consultant: AstraZeneca, Boehringer Ingelheim, Equillium, GlaxoSmithKline, Novartis, Sanofi Regeneron and Teva
- Investigator: AstraZeneca, GlaxoSmithKline, Sanofi Regeneron and Teva
Linda Rogers, MD
- Advisory Board and an Investigator: AstraZeneca
- Investigator: Sanofi Regeneron
Planners and Reviewers
None of the following individuals have any relevant financial relationships to disclose:
Stephanie Corder, ND, RN, CHCP
Andrea Harshman, MHA, CHCP, CMP-HC
Aubrey Shoe, MA
Esther Langmack, MD
Laurie Manka, MD
Amen Sergew, MD
The patient featured in the video segment
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Method of Participation
There are no fees for participating and receiving CME credit for this activity. In order to receive credit for completing the online activity, participants must:
- Read the educational objectives and faculty disclosures.
- Complete the online activity.
- Complete and submit the online evaluation and post-test. Your certificate will be available immediately after submitting the evaluation and post-test.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.